img

Global Therapeutic Peptide Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Therapeutic Peptide Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Polypeptide molecules are ideal drug molecules due to their high affinity, high selectivity, low toxicity and easy synthesis.
The global Therapeutic Peptide market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Therapeutic Peptide is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Therapeutic Peptide is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Therapeutic Peptide is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Therapeutic Peptide include AbbVie, AstraZeneca, Ipsen, Eli Lilly, Merck, Novo Nordisk, Novartis, Johnson and Johnson and Sanofi, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Therapeutic Peptide, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Therapeutic Peptide by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Therapeutic Peptide market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Therapeutic Peptide market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


AbbVie
AstraZeneca
Ipsen
Eli Lilly
Merck
Novo Nordisk
Novartis
Johnson and Johnson
Sanofi
Teva
Takeda
By Type
Oral
Injection
Other
By Application
Cancer
Metabolic Disorders
Central Nervous System
Other
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Therapeutic Peptide in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Therapeutic Peptide manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Therapeutic Peptide sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Therapeutic Peptide Definition
1.2 Market by Type
1.2.1 Global Therapeutic Peptide Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Oral
1.2.3 Injection
1.2.4 Other
1.3 Market Segment by Application
1.3.1 Global Therapeutic Peptide Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Cancer
1.3.3 Metabolic Disorders
1.3.4 Central Nervous System
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Therapeutic Peptide Sales
2.1 Global Therapeutic Peptide Revenue Estimates and Forecasts 2018-2034
2.2 Global Therapeutic Peptide Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Therapeutic Peptide Revenue by Region
2.3.1 Global Therapeutic Peptide Revenue by Region (2018-2024)
2.3.2 Global Therapeutic Peptide Revenue by Region (2024-2034)
2.4 Global Therapeutic Peptide Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Therapeutic Peptide Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Therapeutic Peptide Sales Quantity by Region
2.6.1 Global Therapeutic Peptide Sales Quantity by Region (2018-2024)
2.6.2 Global Therapeutic Peptide Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Therapeutic Peptide Sales Quantity by Manufacturers
3.1.1 Global Therapeutic Peptide Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Therapeutic Peptide Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Therapeutic Peptide Sales in 2022
3.2 Global Therapeutic Peptide Revenue by Manufacturers
3.2.1 Global Therapeutic Peptide Revenue by Manufacturers (2018-2024)
3.2.2 Global Therapeutic Peptide Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Therapeutic Peptide Revenue in 2022
3.3 Global Therapeutic Peptide Sales Price by Manufacturers
3.4 Global Key Players of Therapeutic Peptide, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Therapeutic Peptide Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Therapeutic Peptide, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Therapeutic Peptide, Product Offered and Application
3.8 Global Key Manufacturers of Therapeutic Peptide, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Therapeutic Peptide Sales Quantity by Type
4.1.1 Global Therapeutic Peptide Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Therapeutic Peptide Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Therapeutic Peptide Sales Quantity Market Share by Type (2018-2034)
4.2 Global Therapeutic Peptide Revenue by Type
4.2.1 Global Therapeutic Peptide Historical Revenue by Type (2018-2024)
4.2.2 Global Therapeutic Peptide Forecasted Revenue by Type (2024-2034)
4.2.3 Global Therapeutic Peptide Revenue Market Share by Type (2018-2034)
4.3 Global Therapeutic Peptide Price by Type
4.3.1 Global Therapeutic Peptide Price by Type (2018-2024)
4.3.2 Global Therapeutic Peptide Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Therapeutic Peptide Sales Quantity by Application
5.1.1 Global Therapeutic Peptide Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Therapeutic Peptide Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Therapeutic Peptide Sales Quantity Market Share by Application (2018-2034)
5.2 Global Therapeutic Peptide Revenue by Application
5.2.1 Global Therapeutic Peptide Historical Revenue by Application (2018-2024)
5.2.2 Global Therapeutic Peptide Forecasted Revenue by Application (2024-2034)
5.2.3 Global Therapeutic Peptide Revenue Market Share by Application (2018-2034)
5.3 Global Therapeutic Peptide Price by Application
5.3.1 Global Therapeutic Peptide Price by Application (2018-2024)
5.3.2 Global Therapeutic Peptide Price Forecast by Application (2024-2034)
6 North America
6.1 North America Therapeutic Peptide Sales by Company
6.1.1 North America Therapeutic Peptide Revenue by Company (2018-2024)
6.1.2 North America Therapeutic Peptide Sales Quantity by Company (2018-2024)
6.2 North America Therapeutic Peptide Market Size by Type
6.2.1 North America Therapeutic Peptide Sales Quantity by Type (2018-2034)
6.2.2 North America Therapeutic Peptide Revenue by Type (2018-2034)
6.3 North America Therapeutic Peptide Market Size by Application
6.3.1 North America Therapeutic Peptide Sales Quantity by Application (2018-2034)
6.3.2 North America Therapeutic Peptide Revenue by Application (2018-2034)
6.4 North America Therapeutic Peptide Market Size by Country
6.4.1 North America Therapeutic Peptide Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Therapeutic Peptide Revenue by Country (2018-2034)
6.4.3 North America Therapeutic Peptide Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Therapeutic Peptide Sales by Company
7.1.1 Europe Therapeutic Peptide Sales Quantity by Company (2018-2024)
7.1.2 Europe Therapeutic Peptide Revenue by Company (2018-2024)
7.2 Europe Therapeutic Peptide Market Size by Type
7.2.1 Europe Therapeutic Peptide Sales Quantity by Type (2018-2034)
7.2.2 Europe Therapeutic Peptide Revenue by Type (2018-2034)
7.3 Europe Therapeutic Peptide Market Size by Application
7.3.1 Europe Therapeutic Peptide Sales Quantity by Application (2018-2034)
7.3.2 Europe Therapeutic Peptide Revenue by Application (2018-2034)
7.4 Europe Therapeutic Peptide Market Size by Country
7.4.1 Europe Therapeutic Peptide Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Therapeutic Peptide Revenue by Country (2018-2034)
7.4.3 Europe Therapeutic Peptide Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Therapeutic Peptide Sales by Company
8.1.1 China Therapeutic Peptide Sales Quantity by Company (2018-2024)
8.1.2 China Therapeutic Peptide Revenue by Company (2018-2024)
8.2 China Therapeutic Peptide Market Size by Type
8.2.1 China Therapeutic Peptide Sales Quantity by Type (2018-2034)
8.2.2 China Therapeutic Peptide Revenue by Type (2018-2034)
8.3 China Therapeutic Peptide Market Size by Application
8.3.1 China Therapeutic Peptide Sales Quantity by Application (2018-2034)
8.3.2 China Therapeutic Peptide Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Therapeutic Peptide Sales by Company
9.1.1 APAC Therapeutic Peptide Sales Quantity by Company (2018-2024)
9.1.2 APAC Therapeutic Peptide Revenue by Company (2018-2024)
9.2 APAC Therapeutic Peptide Market Size by Type
9.2.1 APAC Therapeutic Peptide Sales Quantity by Type (2018-2034)
9.2.2 APAC Therapeutic Peptide Revenue by Type (2018-2034)
9.3 APAC Therapeutic Peptide Market Size by Application
9.3.1 APAC Therapeutic Peptide Sales Quantity by Application (2018-2034)
9.3.2 APAC Therapeutic Peptide Revenue by Application (2018-2034)
9.4 APAC Therapeutic Peptide Market Size by Region
9.4.1 APAC Therapeutic Peptide Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Therapeutic Peptide Revenue by Region (2018-2034)
9.4.3 APAC Therapeutic Peptide Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Therapeutic Peptide Sales by Company
10.1.1 Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Therapeutic Peptide Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Therapeutic Peptide Market Size by Type
10.2.1 Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Therapeutic Peptide Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Therapeutic Peptide Market Size by Application
10.3.1 Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Therapeutic Peptide Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Therapeutic Peptide Market Size by Country
10.4.1 Middle East, Africa and Latin America Therapeutic Peptide Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Therapeutic Peptide Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Overview
11.1.3 AbbVie Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 AbbVie Therapeutic Peptide Products and Services
11.1.5 AbbVie Therapeutic Peptide SWOT Analysis
11.1.6 AbbVie Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 AstraZeneca Therapeutic Peptide Products and Services
11.2.5 AstraZeneca Therapeutic Peptide SWOT Analysis
11.2.6 AstraZeneca Recent Developments
11.3 Ipsen
11.3.1 Ipsen Company Information
11.3.2 Ipsen Overview
11.3.3 Ipsen Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Ipsen Therapeutic Peptide Products and Services
11.3.5 Ipsen Therapeutic Peptide SWOT Analysis
11.3.6 Ipsen Recent Developments
11.4 Eli Lilly
11.4.1 Eli Lilly Company Information
11.4.2 Eli Lilly Overview
11.4.3 Eli Lilly Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Eli Lilly Therapeutic Peptide Products and Services
11.4.5 Eli Lilly Therapeutic Peptide SWOT Analysis
11.4.6 Eli Lilly Recent Developments
11.5 Merck
11.5.1 Merck Company Information
11.5.2 Merck Overview
11.5.3 Merck Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Merck Therapeutic Peptide Products and Services
11.5.5 Merck Therapeutic Peptide SWOT Analysis
11.5.6 Merck Recent Developments
11.6 Novo Nordisk
11.6.1 Novo Nordisk Company Information
11.6.2 Novo Nordisk Overview
11.6.3 Novo Nordisk Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Novo Nordisk Therapeutic Peptide Products and Services
11.6.5 Novo Nordisk Therapeutic Peptide SWOT Analysis
11.6.6 Novo Nordisk Recent Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Overview
11.7.3 Novartis Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Novartis Therapeutic Peptide Products and Services
11.7.5 Novartis Therapeutic Peptide SWOT Analysis
11.7.6 Novartis Recent Developments
11.8 Johnson and Johnson
11.8.1 Johnson and Johnson Company Information
11.8.2 Johnson and Johnson Overview
11.8.3 Johnson and Johnson Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Johnson and Johnson Therapeutic Peptide Products and Services
11.8.5 Johnson and Johnson Therapeutic Peptide SWOT Analysis
11.8.6 Johnson and Johnson Recent Developments
11.9 Sanofi
11.9.1 Sanofi Company Information
11.9.2 Sanofi Overview
11.9.3 Sanofi Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Sanofi Therapeutic Peptide Products and Services
11.9.5 Sanofi Therapeutic Peptide SWOT Analysis
11.9.6 Sanofi Recent Developments
11.10 Teva
11.10.1 Teva Company Information
11.10.2 Teva Overview
11.10.3 Teva Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Teva Therapeutic Peptide Products and Services
11.10.5 Teva Therapeutic Peptide SWOT Analysis
11.10.6 Teva Recent Developments
11.11 Takeda
11.11.1 Takeda Company Information
11.11.2 Takeda Overview
11.11.3 Takeda Therapeutic Peptide Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Takeda Therapeutic Peptide Products and Services
11.11.5 Takeda Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Therapeutic Peptide Value Chain Analysis
12.2 Therapeutic Peptide Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Therapeutic Peptide Production Mode & Process
12.4 Therapeutic Peptide Sales and Marketing
12.4.1 Therapeutic Peptide Sales Channels
12.4.2 Therapeutic Peptide Distributors
12.5 Therapeutic Peptide Customers
13 Market Dynamics
13.1 Therapeutic Peptide Industry Trends
13.2 Therapeutic Peptide Market Drivers
13.3 Therapeutic Peptide Market Challenges
13.4 Therapeutic Peptide Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Therapeutic Peptide Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Oral
Table 3. Major Manufacturers of Injection
Table 4. Major Manufacturers of Other
Table 5. Global Therapeutic Peptide Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Therapeutic Peptide Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Therapeutic Peptide Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Therapeutic Peptide Revenue Market Share by Region (2018-2024)
Table 9. Global Therapeutic Peptide Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Therapeutic Peptide Revenue Market Share by Region (2024-2034)
Table 11. Global Therapeutic Peptide Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 12. Global Therapeutic Peptide Sales by Region (2018-2024) & (K Units)
Table 13. Global Therapeutic Peptide Sales Market Share by Region (2018-2024)
Table 14. Global Therapeutic Peptide Sales by Region (2024-2034) & (K Units)
Table 15. Global Therapeutic Peptide Sales Market Share by Region (2024-2034)
Table 16. Global Therapeutic Peptide Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 17. Global Therapeutic Peptide Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Therapeutic Peptide Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Therapeutic Peptide Revenue Share by Manufacturers (2018-2024)
Table 20. Global Therapeutic Peptide Price by Manufacturers 2018-2024 (US$/Unit)
Table 21. Global Key Players of Therapeutic Peptide, Industry Ranking, 2021 VS 2022
Table 22. Global Therapeutic Peptide Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Therapeutic Peptide by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Therapeutic Peptide as of 2022)
Table 24. Global Key Manufacturers of Therapeutic Peptide, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Therapeutic Peptide, Product Offered and Application
Table 26. Global Key Manufacturers of Therapeutic Peptide, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Therapeutic Peptide Sales Quantity by Type (2018-2024) & (K Units)
Table 29. Global Therapeutic Peptide Sales Quantity by Type (2024-2034) & (K Units)
Table 30. Global Therapeutic Peptide Sales Quantity Share by Type (2018-2024)
Table 31. Global Therapeutic Peptide Sales Quantity Share by Type (2024-2034)
Table 32. Global Therapeutic Peptide Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Therapeutic Peptide Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Therapeutic Peptide Revenue Share by Type (2018-2024)
Table 35. Global Therapeutic Peptide Revenue Share by Type (2024-2034)
Table 36. Therapeutic Peptide Price by Type (2018-2024) & (US$/Unit)
Table 37. Global Therapeutic Peptide Price Forecast by Type (2024-2034) & (US$/Unit)
Table 38. Global Therapeutic Peptide Sales Quantity by Application (2018-2024) & (K Units)
Table 39. Global Therapeutic Peptide Sales Quantity by Application (2024-2034) & (K Units)
Table 40. Global Therapeutic Peptide Sales Quantity Share by Application (2018-2024)
Table 41. Global Therapeutic Peptide Sales Quantity Share by Application (2024-2034)
Table 42. Global Therapeutic Peptide Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Therapeutic Peptide Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Therapeutic Peptide Revenue Share by Application (2018-2024)
Table 45. Global Therapeutic Peptide Revenue Share by Application (2024-2034)
Table 46. Therapeutic Peptide Price by Application (2018-2024) & (US$/Unit)
Table 47. Global Therapeutic Peptide Price Forecast by Application (2024-2034) & (US$/Unit)
Table 48. North America Therapeutic Peptide Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Therapeutic Peptide Sales Quantity by Company (2018-2024) & (K Units)
Table 50. North America Therapeutic Peptide Sales Quantity by Type (2018-2024) & (K Units)
Table 51. North America Therapeutic Peptide Sales Quantity by Type (2024-2034) & (K Units)
Table 52. North America Therapeutic Peptide Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Therapeutic Peptide Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Therapeutic Peptide Sales Quantity by Application (2018-2024) & (K Units)
Table 55. North America Therapeutic Peptide Sales Quantity by Application (2024-2034) & (K Units)
Table 56. North America Therapeutic Peptide Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Therapeutic Peptide Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Therapeutic Peptide Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Therapeutic Peptide Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Therapeutic Peptide Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Therapeutic Peptide Sales Quantity by Country (2018-2024) & (K Units)
Table 62. North America Therapeutic Peptide Sales Quantity by Country (2024-2034) & (K Units)
Table 63. Europe Therapeutic Peptide Sales Quantity by Company (2018-2024) & (K Units)
Table 64. Europe Therapeutic Peptide Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Therapeutic Peptide Sales Quantity by Type (2018-2024) & (K Units)
Table 66. Europe Therapeutic Peptide Sales Quantity by Type (2024-2034) & (K Units)
Table 67. Europe Therapeutic Peptide Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Therapeutic Peptide Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Therapeutic Peptide Sales Quantity by Application (2018-2024) & (K Units)
Table 70. Europe Therapeutic Peptide Sales Quantity by Application (2024-2034) & (K Units)
Table 71. Europe Therapeutic Peptide Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Therapeutic Peptide Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Therapeutic Peptide Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Therapeutic Peptide Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Therapeutic Peptide Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Therapeutic Peptide Sales Quantity by Country (2018-2024) & (K Units)
Table 77. Europe Therapeutic Peptide Sales Quantity by Country (2024-2034) & (K Units)
Table 78. China Therapeutic Peptide Sales Quantity by Company (2018-2024) & (K Units)
Table 79. China Therapeutic Peptide Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Therapeutic Peptide Sales Quantity by Type (2018-2024) & (K Units)
Table 81. China Therapeutic Peptide Sales Quantity by Type (2024-2034) & (K Units)
Table 82. China Therapeutic Peptide Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Therapeutic Peptide Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Therapeutic Peptide Sales Quantity by Application (2018-2024) & (K Units)
Table 85. China Therapeutic Peptide Sales Quantity by Application (2024-2034) & (K Units)
Table 86. China Therapeutic Peptide Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Therapeutic Peptide Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Therapeutic Peptide Sales Quantity by Company (2018-2024) & (K Units)
Table 89. APAC Therapeutic Peptide Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Therapeutic Peptide Sales Quantity by Type (2018-2024) & (K Units)
Table 91. APAC Therapeutic Peptide Sales Quantity by Type (2024-2034) & (K Units)
Table 92. APAC Therapeutic Peptide Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Therapeutic Peptide Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Therapeutic Peptide Sales Quantity by Application (2018-2024) & (K Units)
Table 95. APAC Therapeutic Peptide Sales Quantity by Application (2024-2034) & (K Units)
Table 96. APAC Therapeutic Peptide Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Therapeutic Peptide Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Therapeutic Peptide Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Therapeutic Peptide Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Therapeutic Peptide Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Therapeutic Peptide Sales Quantity by Region (2018-2024) & (K Units)
Table 102. APAC Therapeutic Peptide Sales Quantity by Region (2024-2034) & (K Units)
Table 103. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Company (2018-2024) & (K Units)
Table 104. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Type (2018-2024) & (K Units)
Table 106. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Type (2024-2034) & (K Units)
Table 107. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Application (2018-2024) & (K Units)
Table 110. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Application (2024-2034) & (K Units)
Table 111. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Therapeutic Peptide Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Country (2018-2024) & (K Units)
Table 117. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity by Country (2024-2034) & (K Units)
Table 118. AbbVie Company Information
Table 119. AbbVie Description and Overview
Table 120. AbbVie Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 121. AbbVie Therapeutic Peptide Product and Services
Table 122. AbbVie Therapeutic Peptide SWOT Analysis
Table 123. AbbVie Recent Developments
Table 124. AstraZeneca Company Information
Table 125. AstraZeneca Description and Overview
Table 126. AstraZeneca Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 127. AstraZeneca Therapeutic Peptide Product and Services
Table 128. AstraZeneca Therapeutic Peptide SWOT Analysis
Table 129. AstraZeneca Recent Developments
Table 130. Ipsen Company Information
Table 131. Ipsen Description and Overview
Table 132. Ipsen Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 133. Ipsen Therapeutic Peptide Product and Services
Table 134. Ipsen Therapeutic Peptide SWOT Analysis
Table 135. Ipsen Recent Developments
Table 136. Eli Lilly Company Information
Table 137. Eli Lilly Description and Overview
Table 138. Eli Lilly Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 139. Eli Lilly Therapeutic Peptide Product and Services
Table 140. Eli Lilly Therapeutic Peptide SWOT Analysis
Table 141. Eli Lilly Recent Developments
Table 142. Merck Company Information
Table 143. Merck Description and Overview
Table 144. Merck Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 145. Merck Therapeutic Peptide Product and Services
Table 146. Merck Therapeutic Peptide SWOT Analysis
Table 147. Merck Recent Developments
Table 148. Novo Nordisk Company Information
Table 149. Novo Nordisk Description and Overview
Table 150. Novo Nordisk Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 151. Novo Nordisk Therapeutic Peptide Product and Services
Table 152. Novo Nordisk Therapeutic Peptide SWOT Analysis
Table 153. Novo Nordisk Recent Developments
Table 154. Novartis Company Information
Table 155. Novartis Description and Overview
Table 156. Novartis Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 157. Novartis Therapeutic Peptide Product and Services
Table 158. Novartis Therapeutic Peptide SWOT Analysis
Table 159. Novartis Recent Developments
Table 160. Johnson and Johnson Company Information
Table 161. Johnson and Johnson Description and Overview
Table 162. Johnson and Johnson Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 163. Johnson and Johnson Therapeutic Peptide Product and Services
Table 164. Johnson and Johnson Therapeutic Peptide SWOT Analysis
Table 165. Johnson and Johnson Recent Developments
Table 166. Sanofi Company Information
Table 167. Sanofi Description and Overview
Table 168. Sanofi Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 169. Sanofi Therapeutic Peptide Product and Services
Table 170. Sanofi Therapeutic Peptide SWOT Analysis
Table 171. Sanofi Recent Developments
Table 172. Teva Company Information
Table 173. Teva Description and Overview
Table 174. Teva Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 175. Teva Therapeutic Peptide Product and Services
Table 176. Teva Therapeutic Peptide SWOT Analysis
Table 177. Teva Recent Developments
Table 178. Takeda Company Information
Table 179. Takeda Description and Overview
Table 180. Takeda Therapeutic Peptide Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (US$/Unit) and Gross Margin (2018-2024)
Table 181. Takeda Therapeutic Peptide Product and Services
Table 182. Takeda Recent Developments
Table 183. Key Raw Materials Lists
Table 184. Raw Materials Key Suppliers Lists
Table 185. Therapeutic Peptide Distributors List
Table 186. Therapeutic Peptide Customers List
Table 187. Therapeutic Peptide Market Trends
Table 188. Therapeutic Peptide Market Drivers
Table 189. Therapeutic Peptide Market Challenges
Table 190. Therapeutic Peptide Market Restraints
Table 191. Research Programs/Design for This Report
Table 192. Key Data Information from Secondary Sources
Table 193. Key Data Information from Primary Sources
List of Figures
Figure 1. Therapeutic Peptide Product Picture
Figure 2. Global Therapeutic Peptide Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Therapeutic Peptide Market Share by Type in 2022 & 2034
Figure 4. Oral Product Picture
Figure 5. Injection Product Picture
Figure 6. Other Product Picture
Figure 7. Global Therapeutic Peptide Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Therapeutic Peptide Market Share by Application in 2022 & 2034
Figure 9. Cancer
Figure 10. Metabolic Disorders
Figure 11. Central Nervous System
Figure 12. Other
Figure 13. Therapeutic Peptide Report Years Considered
Figure 14. Global Therapeutic Peptide Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Therapeutic Peptide Revenue 2018-2034 (US$ Million)
Figure 16. Global Therapeutic Peptide Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Therapeutic Peptide Sales Quantity 2018-2034 (K Units)
Figure 18. Global Therapeutic Peptide Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Therapeutic Peptide Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Therapeutic Peptide Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Therapeutic Peptide Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Therapeutic Peptide Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Therapeutic Peptide Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Therapeutic Peptide Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Therapeutic Peptide Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Therapeutic Peptide Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Therapeutic Peptide Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Therapeutic Peptide Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Therapeutic Peptide Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Therapeutic Peptide Revenue in 2022
Figure 32. Therapeutic Peptide Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Therapeutic Peptide Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Therapeutic Peptide Revenue Market Share by Type (2018-2034)
Figure 35. Global Therapeutic Peptide Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Therapeutic Peptide Revenue Market Share by Application (2018-2034)
Figure 37. North America Therapeutic Peptide Revenue Market Share by Company in 2022
Figure 38. North America Therapeutic Peptide Sales Quantity Market Share by Company in 2022
Figure 39. North America Therapeutic Peptide Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Therapeutic Peptide Revenue Market Share by Type (2018-2034)
Figure 41. North America Therapeutic Peptide Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Therapeutic Peptide Revenue Market Share by Application (2018-2034)
Figure 43. North America Therapeutic Peptide Revenue Share by Country (2018-2034)
Figure 44. North America Therapeutic Peptide Sales Quantity Share by Country (2018-2034)
Figure 45. United States Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Therapeutic Peptide Sales Quantity Market Share by Company in 2022
Figure 48. Europe Therapeutic Peptide Revenue Market Share by Company in 2022
Figure 49. Europe Therapeutic Peptide Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Therapeutic Peptide Revenue Market Share by Type (2018-2034)
Figure 51. Europe Therapeutic Peptide Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Therapeutic Peptide Revenue Market Share by Application (2018-2034)
Figure 53. Europe Therapeutic Peptide Revenue Share by Country (2018-2034)
Figure 54. Europe Therapeutic Peptide Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 56. France Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 60. China Therapeutic Peptide Sales Quantity Market Share by Company in 2022
Figure 61. China Therapeutic Peptide Revenue Market Share by Company in 2022
Figure 62. China Therapeutic Peptide Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Therapeutic Peptide Revenue Market Share by Type (2018-2034)
Figure 64. China Therapeutic Peptide Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Therapeutic Peptide Revenue Market Share by Application (2018-2034)
Figure 66. APAC Therapeutic Peptide Sales Quantity Market Share by Company in 2022
Figure 67. APAC Therapeutic Peptide Revenue Market Share by Company in 2022
Figure 68. APAC Therapeutic Peptide Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Therapeutic Peptide Revenue Market Share by Type (2018-2034)
Figure 70. APAC Therapeutic Peptide Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Therapeutic Peptide Revenue Market Share by Application (2018-2034)
Figure 72. APAC Therapeutic Peptide Revenue Share by Region (2018-2034)
Figure 73. APAC Therapeutic Peptide Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 78. India Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Therapeutic Peptide Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Therapeutic Peptide Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Therapeutic Peptide Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Therapeutic Peptide Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Therapeutic Peptide Revenue Share by Country (2018-2034)
Figure 87. Brazil Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Therapeutic Peptide Revenue (2018-2034) & (US$ Million)
Figure 92. Therapeutic Peptide Value Chain
Figure 93. Therapeutic Peptide Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed